Bollard Group’s 10x Genomics TXG Stock Holding History

Bollard Group’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20	Closed	-$1K	–	635
2023 Q2	$1K	Buy	+20	New	+$1.08K	﹤0.01%	644

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bollard Group's TXG Position: Q3 2023 in Review

Bollard Group sold out of 10x Genomics (TXG) in Q3 2023, closing a stake of 20 shares — an estimated $1K sold.

Bollard Group first reported a position in TXG in Q2 2023 and held it in 1 quarter. The position peaked at $1K in Q2 2023. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.

Bollard Group reported no remaining 10x Genomics position as of Q3 2023 after selling out during the quarter.
Bollard Group sold 20 10x Genomics shares in Q3 2023, an estimated $1K.
Bollard Group first reported a position in 10x Genomics in Q2 2023 and held it in 1 quarter.
Bollard Group's 10x Genomics position peaked at $1K in Q2 2023.
256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.

Based on Bollard Group's 13F filing for Q3 2023, filed 14 Nov 2023.